Details
Stereochemistry | RACEMIC |
Molecular Formula | C5H11NO2Se |
Molecular Weight | 196.11 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C[Se]CCC(N)C(O)=O
InChI
InChIKey=RJFAYQIBOAGBLC-UHFFFAOYSA-N
InChI=1S/C5H11NO2Se/c1-9-3-2-4(6)5(7)8/h4H,2-3,6H2,1H3,(H,7,8)
Molecular Formula | C5H11NO2Se |
Molecular Weight | 196.11 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
DescriptionCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/28409500 | https://www.ncbi.nlm.nih.gov/pubmed/28285519 | https://www.ncbi.nlm.nih.gov/pubmed/28285519 | https://www.ncbi.nlm.nih.gov/pubmed/28260669
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/28409500 | https://www.ncbi.nlm.nih.gov/pubmed/28285519 | https://www.ncbi.nlm.nih.gov/pubmed/28285519 | https://www.ncbi.nlm.nih.gov/pubmed/28260669
Selenomethionine, DL- is the racemic mixture of the D and L enantiomers of Selenomethionine, that used us animal’s dietary supplement. Selenomethionine, DL- was tolerated by chickens for fattening at up to 1.5 mg selenium supplemented/kg feed; Selenomethionine, DL- is therefore safe for chickens for fattening provided total dietary selenium does not exceed 0.5 mg/kg complete feed; this conclusion is extended to all animal species. Based on available toxicity studies and previous assessments of closely related compounds, it is concluded that selenium from Selenomethionine, DL- does not elicit any adverse effects not expected in a selenium compound. The use of Selenomethionine, DL- in animal nutrition is expected to result in a similar increase in selenium deposition in animal tissues/products as that resulting from other sources of Selenomethionine, DL- . To ensure consumer safety from consumption of food originating from animals fed Selenomethionine, DL-, dietary selenium supplementation from the additive should not exceed a maximum of 0.2 mg Se/kg complete feed. Although a Selenomethionine, DL- containing additive did not release any measurable dust, the additive is considered as a hazard by inhalation, which requires protection measures for users since the additive is not the subject of authorisation, and selenium is highly toxic. The additive is not an irritant to skin and eyes and is not a dermal sensitiser. The use of Selenomethionine, DL- in feed does not pose an additional risk to the environment, compared with other sources of selenium for which it will substitute, as long as the maximum authorised content in complete feed is not exceeded.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28137967
Curator's Comment: Data for L-Selenomethionine
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: WP1050 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28285519 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28285519
Isolated chicken hepatocytes were seeded at a density of 2×10^3 /well in 96-well plates and cultured for 24 h prior to treatment with 0, 0.01, 0.02, 0.05, 0.1, 0.2, 0.4, 0.8, and 1.6 μg/mL AFB1 (Sigma-Aldrich). AFB1 solutions with different concentrations were prepared from a stock solution of 1 mg/mL AFB1 in dimethyl sulfoxide (DMSO). The stock solution was further diluted in culture media at the desired concentrations. The cells were then cultured at 37 °C in a 5% CO2 atmosphere for 24 h to reach 80% confluence and were then subjected to the colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay (Sigma, USA). Absorbance was measured at 490 nm with a reference wavelength of 630 nm.
Various concentrations of SeMet (0, 0.5, 1, 2, and 4 μM) were used to evaluate the protective effect of SeMet against AFB1 toxicity. Compared with the control group, the cell viability in the groups without AFB1 treatment was significant and was promoted by 12% and 13% when SeMet was supplemented at concentrations of 1 and 2 μM, respectively. The group that was treated with 0.05 μg/mL AFB1 had significantly reduced cell viability compared with the control group; however, these reductions were lower when 0.5, 1, 2, and 4 μM SeMet concentrations were supplemented
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:50:52 GMT 2023
by
admin
on
Fri Dec 15 16:50:52 GMT 2023
|
Record UNII |
J9V40V4PKZ
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C275
Created by
admin on Fri Dec 15 16:50:52 GMT 2023 , Edited by admin on Fri Dec 15 16:50:52 GMT 2023
|
||
|
NCI_THESAURUS |
C45565
Created by
admin on Fri Dec 15 16:50:52 GMT 2023 , Edited by admin on Fri Dec 15 16:50:52 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
J9V40V4PKZ
Created by
admin on Fri Dec 15 16:50:52 GMT 2023 , Edited by admin on Fri Dec 15 16:50:52 GMT 2023
|
PRIMARY | |||
|
300000023663
Created by
admin on Fri Dec 15 16:50:52 GMT 2023 , Edited by admin on Fri Dec 15 16:50:52 GMT 2023
|
PRIMARY | |||
|
m9848
Created by
admin on Fri Dec 15 16:50:52 GMT 2023 , Edited by admin on Fri Dec 15 16:50:52 GMT 2023
|
PRIMARY | Merck Index | ||
|
DTXSID7040609
Created by
admin on Fri Dec 15 16:50:52 GMT 2023 , Edited by admin on Fri Dec 15 16:50:52 GMT 2023
|
PRIMARY | |||
|
27585
Created by
admin on Fri Dec 15 16:50:52 GMT 2023 , Edited by admin on Fri Dec 15 16:50:52 GMT 2023
|
PRIMARY | |||
|
215-977-0
Created by
admin on Fri Dec 15 16:50:52 GMT 2023 , Edited by admin on Fri Dec 15 16:50:52 GMT 2023
|
PRIMARY | |||
|
3564
Created by
admin on Fri Dec 15 16:50:52 GMT 2023 , Edited by admin on Fri Dec 15 16:50:52 GMT 2023
|
PRIMARY | |||
|
1464-42-2
Created by
admin on Fri Dec 15 16:50:52 GMT 2023 , Edited by admin on Fri Dec 15 16:50:52 GMT 2023
|
PRIMARY | |||
|
15103
Created by
admin on Fri Dec 15 16:50:52 GMT 2023 , Edited by admin on Fri Dec 15 16:50:52 GMT 2023
|
PRIMARY | |||
|
C826
Created by
admin on Fri Dec 15 16:50:52 GMT 2023 , Edited by admin on Fri Dec 15 16:50:52 GMT 2023
|
PRIMARY |